On the basis of GSK's past performance, why did anyone expect otherwise? These royalties are totally in line with previous quarters.
DS made more money selling Inavir in Japan than GSK did selling Relenza in ROW - forget stockpiling or otherwise, GSK are an embarrassment and the only reason I'd be happy to accept them as the LANI licensee is on the short term super profit that I'd make on selling my holdings.
Out of every pack of Relenza made:
- Biota make 6% - GSK make 94%
I wonder what GSK production costs are? Their sales and marketing costs should be close to zero.
As mentioned earlier, GSK do diddly squat. Biota would be better off contracting out the manufacturing of LANI and hiring some hotshot pharmaceutical sales people - even contracting manufacturing to DS may be the answer.
GSK sold just 6 million pounds worth of Relenza to the whole of Europe last quarter. Anyone like to convince me that GSK sales of Relenza in Europe are even 20% of Roche's sales of Tamiflu?
GSK - what a joke - give me a break!
BTA Price at posting:
$1.29 Sentiment: Hold Disclosure: Held
